Known targets — ChEMBL curated mechanism
ADRB1ADRB2ATP4AATP4BAXLCHRM2CHRM3DRD2FLT3HRH1HTR2AHTR2BHTR2CKCNH2KMT2AMAP2K1MAP2K2MEN1MLNRPLK4RENS1PR1SLC6A2SLC6A4atpAatpBatpCatpDatpEatpFatpFHatpGpol
The experimentally established mechanism targets of Fumaric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 4/20 | 0.48 |
| ▸ | CHRNA4 | P43681 | 4/20 | 0.48 |
| ▸ | PTAFR | P25105 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fumaric Acid SCHEMBL6138320 | 1.00 | CHRNB2 (0.48) | CHRNB2CHRNA4PTAFRKDM4EALDH1A1 | |
| SCHEMBL6138243 | 0.89 | CHRNB2 (0.59) | CHRNB2CHRNA4 | |
| SCHEMBL6138217 | 0.82 | CHRNB2 (0.57) | CHRNB2CHRNA4 | |
| Hydrochloric Acid SCHEMBL6138276 | 0.81 | CHRNB2 (0.56) | CHRNB2CHRNA4 | |
| SCHEMBL6138212 | 0.76 | CHRNB2 (0.54) | CHRNB2CHRNA4 | |
| Hydrochloric Acid SCHEMBL6291509 | 0.74 | CHRNB2 (0.53) | CHRNB2CHRNA4 | |
| SCHEMBL6138415 | 0.72 | CHRNB2 (0.51) | CHRNB2CHRNA4 | |
| SCHEMBL6138316 | 0.71 | CHRNB2 (0.47) | CHRNB2CHRNA4 | |
| SCHEMBL6138302 | 0.71 | NOTUM (0.43) | CHRNB2CHRNA4 | |
| Maleic Acid SCHEMBL31447955 | 0.71 | KMT2A (0.56) | KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1170281-B1 | 1,1- and 1,2-disubstituted cyclopropanes, process for their preparation and pharmaceutical compositions thereof | SERVIER LAB (FR) | 2005-12-21 | — | — | EP | claimed |
| US-6943184-B2 | 1,1- and 1,2-disubstituted cyclopropane compounds | LES LABORATORIES SERVIER (FR) | 2005-09-13 | — | — | US | claimed |
| US-20050032845-A1 | 1,1-and 1,2-disubstituted cyclopropane compounds | GOLDSTEIN SOLO (FR) | 2005-02-10 | — | — | US | claimed |
| US-20020022643-A1 | 1,1- and 1,2-disubstituted cyclopropane compounds | ADIR ET COMPAGNIE (FR) | 2002-02-21 | — | — | US | claimed |
| US-6943184-B2 | 1,1- and 1,2-disubstituted cyclopropane compounds | LES LABORATORIES SERVIER (FR) | 2005-09-13 | — | — | US | disclosed |
| US-20050032845-A1 | 1,1-and 1,2-disubstituted cyclopropane compounds | GOLDSTEIN SOLO (FR) | 2005-02-10 | — | — | US | disclosed |
| US-20020022643-A1 | 1,1- and 1,2-disubstituted cyclopropane compounds | ADIR ET COMPAGNIE (FR) | 2002-02-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050032845-A1 | 1,1-and 1,2-disubstituted cyclopropane compounds | CHRNA1, CHRNA4, CHRNB1 | CHRNB2 24/4885CHRNA4 2/4885PTAFR 1203/4885 |
| US-20020022643-A1 | 1,1- and 1,2-disubstituted cyclopropane compounds | HCAR1, CHRNA1, CNR1 | CHRNB2 48/4885CHRNA4 31/4885PTAFR 1477/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.